Latest news with #Capstan
South China Morning Post
3 days ago
- Entertainment
- South China Morning Post
How Ayrton Senna shared a distinction with late Hong Kong kart racer Paul Tarrant
Whizzing around Victoria Park in the 1970s, Hong Kong kart racer Paul Tarrant embodied a freewheeling era and a city gathering speed. Tarrant, who died this month aged 68, competed for the last time on home soil when he finished as top local driver in the 1974 Hong Kong International Karting Prix (HKIKP). By then, his short but successful career had launched him on to the silver screen and featured duels with a rival later dubbed 'the man Ayrton Senna could never beat': Terry Fullerton. Sepia footage captures a track marked out with cones and tyres, and a stream of karts hurtling down a straight towards crowds of enthusiasts with cameras ready, in the shadows of a smattering of high-rise buildings. An excited announcer relays the action and the winners receive cartons of Capstan cigarettes. How the Post reported the HK International Karting Prix in 1974. Photo: SCMP Tarrant had the dashing looks to accompany his talent, even if, weeks earlier, a barber at Singapore's old airport sheared his locks when he arrived for an event, because of the city state's rule against men having long hair. With his go-faster trim, Tarrant won every race.
Business Wire
30-04-2025
- Business
- Business Wire
Capstan Therapeutics to Participate in Upcoming Scientific Conferences and Present New Preclinical Data in Support of Lead Anti-CD19 In Vivo CAR-T Candidate, CPTX2309
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. ('Capstan'), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will present at upcoming scientific conferences and showcase new preclinical data on CPTX2309, Capstan's lead anti-CD19 in vivo CAR-T candidate, at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA. 'Among the diverse set of presentations showcasing Capstan's non-viral CellSeeker™ platform, we are particularly encouraged by new preclinical data in support of our in vivo anti-CD19 CAR-T program, which demonstrate that a compact two-dose cycle was sufficient to induce rapid and deep B cell depletion in blood and tissues of non-human primates,' said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. 'These preclinical data highlight the potency of B cell depletion achievable with a transient in vivo CAR mRNA approach, without the need for lymphodepletion, and set the stage for clinical evaluation of CPTX2309.' Featured Presentation: American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting Date: Location: New Orleans, LA Oral presentation title: A Two-Infusion Regimen with a Novel In Vivo Non-Viral Chimeric Antigen Receptor (CAR) Achieves up to 90% CD8+ T Cell Engineering and Tissue Depletion of Target Cells in Non-Human Primates (NHPs) Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder Session title: CAR T Innovations in Autoimmune and Infectious Disease and Allergy Date and time: May 15, 2025, 5:00 p.m. - 5:15 p.m. CT Location: Room 393-396 Additional Presentations feature progress with our CellSeeker TM platform technology applicable to both mRNA and gene editing payloads: Cellicon Valley '25: The Future of Cell and Gene Therapies Date: Apr 30-May 2, 2025 Location: Philadelphia, PA Oral Presentation Title: Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders Presenter: Laura Shawver, Ph.D., Chief Executive Officer Session title: Plenary Session 2, Leadership in Cell and Gene Therapies: The XX Factor Date and Time: May 1, 2025, 10:20 a.m. - 10:30 a.m. ET International Society of Cell & Gene Therapy (ISCT) 2025 Date: May 7-10, 2025 Location: New Orleans, LA Poster title: Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder Poster number: 901 Session title: Poster Networking Reception 1; Immunotherapy (CAR-T, T Reg, NK Cells, etc.) Date and time: May 7, 2025, 7:00 p.m. - 8.30 p.m. CT 21 st Annual PEGS Boston: The Essential Protein & Antibody Engineering Summit Date: May 12-16, 2025 Location: Omni Boston Hotel at the Seaport, Boston, MA Title: Chairperson's Remarks Presenter: Adrian Bot, M.D., Ph.D., Chief Scientific Officer Track: In Vivo CAR T Engineering: Moving into the Clinic Date and time: May 15, 2025, 8:25 a.m. ET Oral presentation title: In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders Presenter: John Rossi, Vice President, Translational Medicine Track: In Vivo CAR T Engineering: Moving into the Clinic Date and time: May 15, 2025, 9:00 a.m. ET American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting Date: May 13-17, 2025 Location: New Orleans, LA Science Symposium: Targeted Nanosystems For Gene Transfer And Editing: Beyond Delivery To The Liver Oral presentation title: In vivo immune cell engineering using targeted nanoparticles Presenter: Priya Karmali, Ph.D., Chief Technology Officer Date and time: May 16, 2025, 4:10 p.m. - 4:35 p.m. CT Location: NOLA Theater B Poster: Efficient In Vivo Gene Editing of T Cells Utilizing Novel Targeted Lipid Nanoparticles Presenter: Esther Chen, Ph.D., Principal Scientist, R&D Session title: Tuesday Poster Reception Date and time: May 13, 2025, 6:00 p.m. - 7:30 p.m. CT Location: Poster Hall I2 Poster: Effective Gene Editing in Hematopoietic Stem and Progenitor Cells (HSPCs) through a Novel Targeted Lipid Nanoparticle Presenter: Esther Chen, Ph.D., Principal Scientist, R&D Session title: Thursday Poster Reception Date and time: May 15, 2025, 5:30 p.m. - 7:00 p.m. CT Location: Poster Hall I2 TIDES USA Date: May 19-22, 2025 Location: Manchester Grand Hyatt San Diego, San Diego, CA Oral presentation title: In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles Presenter: Priya Karmali, Ph.D., Chief Technology Officer Track: mRNA Technology and Applications Date and time: May 21, 2025, 2:00 p.m. PT About Capstan Therapeutics, Inc. ( Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan's CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit and follow us on LinkedIn.
